⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10513825 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL17597679 | 0.78 | GABRP (0.31) | — | |
| Hydrochloric Acid SCHEMBL17595132 | 0.78 | GABRP (0.31) | — | |
| Xylose SCHEMBL25218512 | 0.77 | — | — | |
| Adenine SCHEMBL2942772 | 0.75 | LMNA (0.54) | — | |
| SCHEMBL5660574 | 0.74 | — | — | |
| Trifluoroacetic Acid SCHEMBL17595019 | 0.71 | — | — | |
| SCHEMBL7853156 | 0.68 | — | — | |
| SCHEMBL2537740 | 0.65 | — | — | |
| SCHEMBL10377486 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127804-A1 | RIBOSE LINKERS AND CONJUGATES THEREOF | UNIVERSITY OF SOUTH ALABAMA | 2025-04-24 | — | — | US | claimed |
| EP-4472993-A2 | RIBOSE LINKERS AND CONJUGATES THEREOF | Elysium Health, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| CN-118632855-A | Ribose linker and conjugates thereof | 益力舒健康公司 | 2024-09-10 | — | — | CN | claimed |
| WO-2024098042-A2 | GROWTH-BASED SELECTION PLATFORM FOR NONCANONICAL COFACTOR OXIDIZING ENZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-10 | — | — | WO | claimed |
| WO-2023150667-A2 | RIBOSE LINKERS AND CONJUGATES THEREOF | ELYSIUM HEALTH INC. (US) | 2023-08-10 | — | — | WO | claimed |
| EP-4216950-A1 | METHODS OF AMELIORATING THE EFFECTS OF ALCOHOLIC LIVER DAMAGE | Fulgent Life Inc. (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2022211821-A1 | METHODS OF AMELIORATING THE EFFECTS OF ALCOHOLIC LIVER DAMAGE | Fulgent Life Inc. (US) | 2022-10-06 | — | — | WO | claimed |
| US-11376271-B1 | Methods of ameliorating the effects of alcoholic liver damage | Fulgent Life Inc. (US) | 2022-07-05 | — | — | US | claimed |
| EP-3600312-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | claimed |
| EP-3490982-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2019-06-05 | — | — | EP | claimed |
| WO-2018183145-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | claimed |
| WO-2018020242-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-02-01 | — | — | WO | claimed |
| EP-2723717-A2 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2014-04-30 | — | — | EP | claimed |
| WO-2012177893-A2 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2012-12-27 | — | — | WO | claimed |
| EP-2271624-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | claimed |
| WO-2010126914-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | claimed |
| WO-2009131245-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | WO | claimed |
| WO-2003057688-A2 | OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-07-17 | — | — | WO | claimed |
| JP-60184252-A | — | — | None | — | — | JP | disclosed |
| US-3884971-A | Reduction of carbonyl compounds | MOBIL OIL CORP | 1975-05-20 | — | — | US | disclosed |